{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:03:43Z","timestamp":1770750223894,"version":"3.50.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11102-019-00989-1","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T21:33:02Z","timestamp":1569447182000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Dopamine agonists in prolactinomas: when to withdraw?"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1359-814X","authenticated-orcid":false,"given":"Pedro","family":"Souteiro","sequence":"first","affiliation":[]},{"given":"Sandra","family":"Belo","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"issue":"2","key":"989_CR1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96(2):273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"989_CR2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","volume":"14","author":"V dos Santos Nunes","year":"2011","unstructured":"dos Santos Nunes V et al (2011) Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14(3):259\u2013265","journal-title":"Pituitary"},{"issue":"1","key":"989_CR3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","volume":"53","author":"A Di Sarno","year":"2000","unstructured":"Di Sarno A et al (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53(1):53\u201360","journal-title":"Clin Endocrinol (Oxf)"},{"key":"989_CR4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109:42\u201350","journal-title":"Neuroendocrinology"},{"issue":"2","key":"989_CR5","first-page":"125","volume":"78","author":"CC Zygourakis","year":"2017","unstructured":"Zygourakis CC et al (2017) Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neurol Surg Part B 78(2):125\u2013131","journal-title":"J Neurol Surg Part B"},{"issue":"4","key":"989_CR6","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.4158\/EP161709.CO","volume":"3","author":"S Ananthakrishnan","year":"2017","unstructured":"Ananthakrishnan S (2017) The dark side of dopamine agonist therapy in prolactinoma management. AACE Clin Case Rep 3(4):e384\u2013e386","journal-title":"AACE Clin Case Rep"},{"issue":"6","key":"989_CR7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I et al (2014) Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case\u2013control study. Clin Endocrinol 80(6):863\u2013868","journal-title":"Clin Endocrinol"},{"issue":"13","key":"989_CR8","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/mds.21639","volume":"22","author":"G Simonis","year":"2007","unstructured":"Simonis G, Fuhrmann JT, Strasser RH (2007) Meta-analysis of heart valve abnormalities in Parkinson\u2019s disease patients treated with dopamine agonists. Mov Disord 22(13):1936\u20131942","journal-title":"Mov Disord"},{"issue":"2","key":"989_CR9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11594940-000000000-00000","volume":"35","author":"G Trifir\u00f2","year":"2012","unstructured":"Trifir\u00f2 G et al (2012) Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson\u2019s disease and hyperprolactinaemia. Drug Saf 35(2):159\u2013171","journal-title":"Drug Saf"},{"issue":"1","key":"989_CR10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2265.2003.01678.x","volume":"58","author":"S Mehmet","year":"2003","unstructured":"Mehmet S, Powrie JK (2003) A survey of dopamine agonist withdrawal policy in UK endocrinologists treating patients with prolactinomas. Clin Endocrinol 58(1):111\u2013113","journal-title":"Clin Endocrinol"},{"issue":"2","key":"989_CR11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11102-016-0767-5","volume":"20","author":"SA Beshyah","year":"2017","unstructured":"Beshyah SA et al (2017) Management of prolactinomas: a survey of physicians from the Middle East and North Africa. Pituitary 20(2):231\u2013240","journal-title":"Pituitary"},{"issue":"10","key":"989_CR12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1530\/EC-18-0250","volume":"7","author":"J Lijin","year":"2018","unstructured":"Lijin J et al (2018) Management of prolactinoma: a survey of endocrinologists in China. Endocr Connect 7(10):1013\u20131019","journal-title":"Endocr Connect"},{"issue":"4","key":"989_CR13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11102-017-0806-x","volume":"20","author":"M Teixeira","year":"2017","unstructured":"Teixeira M, Souteiro P, Carvalho D (2017) Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal. Pituitary 20(4):464\u2013470","journal-title":"Pituitary"},{"issue":"5","key":"989_CR14","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/0002-9343(83)90418-7","volume":"75","author":"DG Johnston","year":"1983","unstructured":"Johnston DG et al (1983) Hyperprolactinemia. Long-term effects of bromocriptine. Am J Med 75(5):868\u2013874","journal-title":"Am J Med"},{"issue":"2","key":"989_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/acta.0.1040139","volume":"104","author":"A Zarate","year":"1983","unstructured":"Zarate A et al (1983) Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh) 104(2):139\u2013142","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"4","key":"989_CR16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1210\/jcem-60-4-764","volume":"60","author":"P Moriondo","year":"1985","unstructured":"Moriondo P et al (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60(4):764\u2013772","journal-title":"J Clin Endocrinol Metab"},{"issue":"8396","key":"989_CR17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(84)90480-X","volume":"2","author":"DG Johnston","year":"1984","unstructured":"Johnston DG et al (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet 2(8396):187\u2013192","journal-title":"Lancet"},{"issue":"2","key":"989_CR18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0015-0282(16)47593-X","volume":"41","author":"WS Maxson","year":"1984","unstructured":"Maxson WS et al (1984) Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil Steril 41(2):218\u2013223","journal-title":"Fertil Steril"},{"issue":"3","key":"989_CR19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2265.1987.tb01163.x","volume":"27","author":"C Wang","year":"1987","unstructured":"Wang C et al (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol (Oxf) 27(3):363\u2013371","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"989_CR20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","volume":"34","author":"JW van\u2019t Verlaat","year":"1991","unstructured":"van\u2019t Verlaat JW, Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34(3):175\u2013178","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"989_CR21","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","volume":"87","author":"VQ Passos","year":"2002","unstructured":"Passos VQ et al (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87(8):3578\u20133582","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"989_CR22","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J et al (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904\u2013909","journal-title":"N Engl J Med"},{"issue":"21","key":"989_CR23","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"Colao A et al (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349(21):2023\u20132033","journal-title":"N Engl J Med"},{"issue":"9","key":"989_CR24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03348016","volume":"20","author":"M Muratori","year":"1997","unstructured":"Muratori M et al (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20(9):537\u2013546","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"989_CR25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF03343573","volume":"22","author":"S Cannavo","year":"1999","unstructured":"Cannavo S et al (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22(5):354\u2013359","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"989_CR26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","volume":"59","author":"MY Xia","year":"2018","unstructured":"Xia MY et al (2018) Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine 59(1):50\u201361","journal-title":"Endocrine"},{"issue":"1","key":"989_CR27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"Dekkers OM et al (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43\u201351","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"989_CR28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11102-014-0617-2","volume":"18","author":"J Hu","year":"2015","unstructured":"Hu J et al (2015) kcolCurrent drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 18(5):745\u2013751","journal-title":"Pituitary"},{"issue":"3","key":"989_CR29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/jcem-59-3-463","volume":"59","author":"M Gen","year":"1984","unstructured":"Gen M et al (1984) Necrotic changes in prolactinomas after long term administration of bromocriptine. J Clin Endocrinol Metab 59(3):463\u2013470","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"989_CR30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1210\/jcem-58-6-1179","volume":"58","author":"AM Landolt","year":"1984","unstructured":"Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58(6):1179\u20131183","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"989_CR31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","volume":"68","author":"J Schlechte","year":"1989","unstructured":"Schlechte J et al (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68(2):412\u2013418","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"989_CR32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0015-0282(16)59292-9","volume":"48","author":"DA Sisam","year":"1987","unstructured":"Sisam DA, Sheehan JP, Sheeler LR (1987) The natural history of untreated microprolactinomas. Fertil Steril 48(1):67\u201371","journal-title":"Fertil Steril"},{"issue":"2","key":"989_CR33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF et al (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65(2):265\u2013273","journal-title":"Clin Endocrinol"},{"issue":"1","key":"989_CR34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","volume":"63","author":"M Biswas","year":"2005","unstructured":"Biswas M et al (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63(1):26\u201331","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"989_CR35","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"Kharlip J et al (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94(7):2428\u20132436","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"989_CR36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","volume":"67","author":"A Colao","year":"2007","unstructured":"Colao A et al (2007) Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol 67(3):426\u2013433","journal-title":"Clin Endocrinol"},{"issue":"1","key":"989_CR37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-011-0303-6","volume":"15","author":"P Anagnostis","year":"2012","unstructured":"Anagnostis P et al (2012) Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 15(1):25\u201329","journal-title":"Pituitary"},{"issue":"10","key":"989_CR38","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0043-112861","volume":"125","author":"B Araujo","year":"2017","unstructured":"Araujo B, Belo S, Carvalho D (2017) Pregnancy and tumor outcomes in women with prolactinoma. Exp Clin Endocrinol Diabetes 125(10):642\u2013648","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"989_CR39","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12370","volume":"80","author":"M-E Domingue","year":"2014","unstructured":"Domingue M-E et al (2014) Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol 80(5):642\u2013648","journal-title":"Clin Endocrinol"},{"issue":"1","key":"989_CR40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1210\/jc.2012-3039","volume":"98","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS et al (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98(1):372\u2013379","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"989_CR41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/09513590.2016.1254177","volume":"33","author":"A Rastogi","year":"2017","unstructured":"Rastogi A, Bhadada SK, Bhansali A (2017) Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol Endocrinol 33(4):270\u2013273","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"989_CR42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11102-005-5083-4","volume":"8","author":"MD Bronstein","year":"2005","unstructured":"Bronstein MD (2005) Prolactinomas and pregnancy. Pituitary 8(1):31\u201338","journal-title":"Pituitary"},{"issue":"1","key":"989_CR43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1590\/2359-3997000000138","volume":"60","author":"MS Mallea-Gil","year":"2016","unstructured":"Mallea-Gil MS et al (2016) Prolactinomas: evolution after menopause. Arch Endocrinol Metab 60(1):42\u201346","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"989_CR44","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cen.13765","volume":"89","author":"S Santharam","year":"2018","unstructured":"Santharam S et al (2018) Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol 89(3):346\u2013353","journal-title":"Clin Endocrinol"},{"issue":"2","key":"989_CR45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12672-019-00363-4","volume":"10","author":"R Indirli","year":"2019","unstructured":"Indirli R et al (2019) Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas. Horm Cancer 10(2):120\u2013127","journal-title":"Horm Cancer"},{"issue":"3","key":"989_CR46","first-page":"461","volume":"19","author":"N Ristic","year":"2017","unstructured":"Ristic N et al (2017) Effects of estradiol on histological parameters and secretory ability of pituitary mammotrophs in ovariectomized female rats. Cell J 19(3):461\u2013468","journal-title":"Cell J"},{"issue":"3","key":"989_CR47","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11102-016-0708-3","volume":"19","author":"SC Dogansen","year":"2016","unstructured":"Dogansen SC et al (2016) Withdrawal of dopamine agonist therapy in prolactinomas: in which patients and when? Pituitary 19(3):303\u2013310","journal-title":"Pituitary"},{"issue":"5","key":"989_CR48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11102-013-0525-x","volume":"17","author":"R Kwancharoen","year":"2014","unstructured":"Kwancharoen R et al (2014) Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary 17(5):451\u2013456","journal-title":"Pituitary"},{"key":"989_CR49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fendo.2015.00011","volume":"6","author":"L Vilar","year":"2015","unstructured":"Vilar L et al (2015) Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile? Front Endocrinol 6:11","journal-title":"Front Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-019-00989-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-019-00989-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-019-00989-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T01:57:04Z","timestamp":1600912624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-019-00989-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1007\/s11102-019-00989-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"25 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}